Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 [1st part]. Quality of life: Application of EORTC QLQ-C30 instrument;Resultados del uso en cancer de prostata del bloqueo androgénico completo en area de salud con hospital de referencia tipo 2 (1α parte). calidad de vida: aplicación del instrumento EORTC QLQ-C30

Archivos Espanoles de Urologia

Volumn 62, Issue 6, 2009, Pages 431-459

  Guerra, Nicolás Alberto Cruz ^a,b  

^a Complejo Asistencial de Zamora ^*  (Spain)

^b Hospital Provincial de Zamora   (Spain)

Author keywords

Hormonal therapy; Prostate cancer; Quality of life

Indexed keywords

ANTIANDROGEN;

ADENOCARCINOMA; AGED; ARTICLE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATE TUMOR; QUALITY OF LIFE; QUESTIONNAIRE;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 70449507443     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen mayor cancers in 1985. Int J Cancer 1993; 54: 594-606.
2. Blázquez Izquierdo J, San José Manso L, Jiménez Penick J, Delgado Martín JA. Historia natural, etiopatogenia y clínica del cáncer de próstata. En: Resel Estévez L, Moreno Sierra J, editores. Tratado de Oncología Urológica, p. 719-28. Sanidad y Ediciones. Madrid; 2003.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
4. Bray F, Sankila R, Ferlay J, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166.
5. Black RJ, Bray F, Ferlay J, et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-107.
6. Granado de la Orden S, Saá Requejo C, Quintás Viqueira A. Situación epidemiológica del cáncer de próstata en España. Actas Urol Esp 2006; 30: 574-82.
7. Herranz Amo F. El Cáncer de Próstata en la Comunidad de Madrid en el año 2000. AstraZeneca. Madrid; 2001.
8. Mariani AJ. Terapia de supresión androgénica en el cáncer de próstata: un ejercicio de gestión de recursos. En: Resel Estévez L, Ruiz de la Roja JC, Sánchez Sánchez E, editores. AUA Update Series. Actualización en Urología, (ed. española 2003). p. 25-32. Medical Trends. Barcelona; 2002.
9. Crawford ED, Bennett CL, Stone NN, et al. Comparison of perspectives on prostate cancer: analyses of survey data. Urology 1997; 50: 366-72.
10. King CR. Overview of quality of life and controversial issues. En: King CR, Hinds PS (editores). Quality of life from nursing and patient perspectives, p. 23-34. Jones & Bartlett. Boston; 1998.
11. Patrick D, Erickson P. Assessing health-related quality of life for clinical decision making. En: Walker SR, Rosser RM, editors. Quality of Life, assessment and application, p. 9-49. MTP Press. Lancaster, England; 1988.
12. W.H.O. Constitution of the World Health Organization, basic documents. WHO. Geneva; 1948.
13. Peiró i Moreno S. Calidad de vida. En: Ruiz López P, Alcalde Escribano J, Landa García JI, editores. Gestión clínica en Cirugía, p. 317-37. Arán Ediciones. Madrid; 2005.
14. The EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
15. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
16. McNaughton-Collins M, Walker-Corkery E, Barry MJ. Health-related Quality of Life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000. J Natl Cancer Inst Monogr 2004; 33: 78101.
17. Litwin MS, Hays RD, Fink A, et al. Quality-oflife outcomes in men treated for localized prostate cancer. J A M A 1995; 273: 129-35.
18. Borghede G, Karlsson J, Sullivan M. Quality of life in patients with prostatic cancer: results from a Swedish population study. J Urol 1997; 158: 1477-85.
19. Albertsen PC, Aaronson NK, Muller MJ, et al. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997; 49: 207-216.
20. Phillips C, Thompson G. What is a QALY? [monografía en Internet]. En: What is...? series. 1 (6): 1-6. Hayward Medical Communications. London; 2001 [acceso 15 noviembre 2005]. Disponible en: http://www.evidence-based medicine.co.uk/ ebmfiles/WhatisaQALY.pdf
21. Gold MR, Russell LB, Seigel JE, Weinstein MC, editores. Cost-effectiveness in health and medicine. Oxford University Press. New York; 1996.
22. Ridao López M. Evaluación económica. En: Ruiz López P, Alcalde Escribano J, Landa García JI, editores. Gestión clínica en Cirugía, p. 383-400. Arán Ediciones. Madrid; 2005.
23. Petrou S. What are health utilities? [monografía en Internet]. En: What is...? series. 1 (4): 1-5. Hayward Medical Communications. London; 2003 [acceso 15 noviembre 2005]. Disponible en: http://www.evidencebasedmedicine.co. uk/ebmfiles/ Whatarehealthutil.pdf
24. Tsuchiya A, Dolan P. The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Making 2005; 25: 460-467.
25. Bennett CL, Matchar D, McCrory D, et al. Costeffective models for flutamide for prostate carcinoma patients. Are they helpful to policy makers? Cancer 1996; 77: 1854-61.
26. Malek M. Implementing QALYs [monografía en Internet]. En: What is...? series. 2 (1): 1-7. Hayward Medical Communications. London; 2001 [acceso 15 noviembre 2005]. Disponible en: http://www.evidence-based-medicine.co.uk /ebmfiles/ImplementQALYs.pdf
27. Fleurence R. Pharmacoeconomics. (1) An introduction to health economics. Pharm J 2003; 271: 679-81.
28. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323: 1300-3.
29. M.S.C. Datos relevantes sobre la salud de los españoles. En: Sistema Nacional de Salud, p. 6576. Ministerio de Sanidad y Consumo. Madrid; 2006.
30. INEbase [base de datos en Internet]. Instituto Nacional de Estadística. Madrid: [actualizada en 11 de noviembre de 2006; accceso 15 de noviembre de 2006]. Disponible en: http://www.ine.es/inebase2/leer.jsp?L= 0&divi=IDB&his=0
31. Junta de Castilla y León [sede Web]. Dirección General de Estadística de la Junta de Castilla y León; 2006 [accceso 15 de noviembre de 2006]. Padrón Municipal de Habitantes a 1 de enero de 2005. Población (a 01/01/2005) por edad (grupos quinquenales) según sexo. Zamora. Disponible en: http://www.jcyl.es/jcyl-client/jcyl/ch/dge/tkC ontent?idContent=41925
32. O'Connor KM, Fitzpatrick JM. Side-effects of treatments for locally advanced prostate cancer. B J U Int 2006; 97: 22-8.
33. Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 2006; 54: 85-90.
34. Schröder FH. Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. B J U Int 1999; 83: 161-70.
35. Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing 2004; 33: 548-55.
36. Gogov S, Hussain F, Naglie G, et al. Is physical function affected by androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer? J Clin Oncol 2006; 24, 18 (June 20 Supplement): 4615.
37. Holmes-Walker DJ, Woo H, Gurney H, et al. Maintaining bone health in patients with prostate cancer. Med J Aust 2006; 184: 176-9.
38. Tyrrell CJ, Blake GM, Iversen P, et al. The nonsteroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World J Urol 2003; 21: 37-42.
39. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167: 1952-6.
40. Carmack Taylor CL, Demoor C, Smith MA, et al. Active for Life After Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psychooncology 2006; 15: 847-62.
41. Hunt-Shanks TT, Blanchard CM, Baker F, et al. Exercise use as complementary therapy among breast and prostate cancer survivors receiving active treatment: examination of exercise intention. Integr Cancer Ther 2006; 5: 109-16.
42. Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21: 1653-9.
43. Stevinson C, Fox KR. Feasibility of an exercise rehabilitation programme for cancer patients. Eur J Cancer Care (Engl) 2006; 15: 386-96.
44. Kunkel EJ, Bakker JR, Myers RE, et al. Biopsychosocial aspects of prostate cancer. Psychosomatics 2000; 41: 85-94.
45. Roth AJ, Kornblith AB, Batel-Copel L, et al. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer 1998; 82: 1904-8.
46. Davison BJ, Degner LF. Empowerment of men newly diagnosed with prostate cancer. Cancer Nurs 1997; 20: 187-96.
47. Roth AJ, Scher HI: Genitourinary malignancies. En: Holland JC, editor. Psycho-Oncology. Oxford University Press. New York; 1998.
48. Hardy MP, Ganjam VK. Stress, 11beta-HSD, and Leydig cell function. J Androl 1997; 18: 475-9.
49. Whelan P. Are we promoting stress and anxiety? BM J 1997; 315: 1549-50.
50. Kornblith AB, Herr HW, Ofman US, et al. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer 1994; 73: 2791-802.
51. Clark JA, Wray N, Brody B, et al. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med 1997; 45: 1299-309.
52. McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995; 52: 89-99.
53. Schweiger U, Deuschle M, Weber B, et al. Testosterone, gonadotropin, and Cortisol secretion in male patients with major depression. Psychosom Med 1999; 61: 292-6.
54. Maes M, Lin A, Bonaccorso S, et al. Increased 24-hour urinary Cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998; 98: 328-35.
55. Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med 1984; 46:199-212.
56. Heim HM, Oei TP. Comparison of prostate cancer patients with and without pain. Pain 1993; 53: 159-62.
57. Monti DA, Kunkel EJ. Management of chronic pain among elderly patients. Psychiatr Serv 1998; 49: 1537-9.
58. Almeida OP, Waterreus A, Spry N, et al. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004; 29: 1071-81.
59. Silverman I, Kastuk D, Choi J, et al. Testosterone levels and spatial ability in men. Psychoneuroendocrinology 1999; 24:813-822.
60. Kimura D, Hampson E. Cognitive pattern in men and women is influenced by fluctuations in sex hormones. Curr Dir Psychol Sci 1994; 3: 57-61.
61. Gordon HW, Stoffer DS, Lee PA. Ultradian rhythms in performance on tests of specialized cognitive function. Int J Neurosci 1995; 83: 199-211.
62. Australian Department of Human Services and Health. Adverse Drug Reactions System. Informes números 82994 y 107214. Australian Department of Human Services and Health. Canberra; 1997.
63. Gouchie C, Kimura D. The relationship between testosterone levels and cognitive ability patterns. Psychoneuroendocrinology 1991; 16: 323-34.
64. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994; 108: 325-32.
65. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-7.
66. Green HJ, Pakenham KI, Headley BC, et al. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology 2002; 11:401-14.
67. Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. B J U Int 2004 ; 93: 975-9.
68. Newton C, Slota D, Yuzpe AA, et al. Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study. Fertil Steril 1996; 65: 1253-5.
69. Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 2003; 170: 1808-11.
70. Nayeri K, Pitaro G, Feldman JG. Marital status and stage at diagnosis in cancer. N Y State J Med 1992; 92:8-11.
71. Jakobsson L, Hallberg IR, Loven L. Experiences of daily life and life quality in men with prostate cancer. An explorative study. Part I. Eur J Cancer Care (Engl) 1997; 6: 108-116.
72. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000; 163: 1743-6.
73. Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002; 94: 430-7.
74. Stone P, Hardy J, Huddart R, et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36: 1134-41.
75. Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998; 90: 1537-44.
76. Burnham TR, Wilcox A. Effects of exercise on physiological and psychological variables in cancer survivors. Med Sci Sports Exerc 2002; 34: 1863-7.
77. Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001; 18: 187-92.
78. Langenstroer P, Porter HJ 2nd, McLeod DG, et al. Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases. J Urol 2004; 171(2 Pt 1): 684-6.
79. Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005; 7(Suppl 5): S37-S43.
80. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592-6.
81. Galasko CS. Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976; 263: 507-8.
82. Siegal T, Siegal T. Current considerations in the management of neoplastic spinal cord compression. Spine 1989; 14: 223-8.
83. Sandblom G, Carlsson P, Sigsjo P, et al. Pain and health-related quality of life in a geographically defined population of men with prostate cancer. Br J Cancer 2001 ; 85: 497-503.
84. Drayer RA, Henderson J, Reidenberg M. Barriers to better pain control in hospitalized patients. J Pain Symptom Manage 1999; 17: 434-40.
85. Sandblom G, Carlsson P, Sennfalt K, et al. A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer 2004; 90: 1163-8.
86. Sennfalt K, Carlsson P, Sandblom G, et al. The estimated economic value of the welfare loss due to prostate cancer pain in a defined population. Acta Oncol 2004; 43: 290-6.
87. Southwest Oncology Group; Berry DL, Moinpour CM, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006; 24: 2828-35.
88. Di lorenzo G, Autorino R, Ciardiello F, et al. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life. Oncol Rep 2003; 10: 399-404.
89. Turner SL, Gruenewald S, Spry N, et al. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 2001; 84: 297-302.
90. Nilsson S, Strang P, Ginman C, et al. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. J Pain Symptom Manage 2005; 29: 352-7.
91. Weinfurt KP, Anstrom KJ, Castel LD, et al. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 2006; 17: 986-9.
92. Van Veldhuizen PJ, Taylor SA, Williamson S, et al. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J Urol 2000; 163: 187-190.
93. Loscalzo M, Jacobsen PB. Practical behavioral approaches to the effective management of pain and distress. J Psychosoc Oncol 1990; 8:139-69.
94. Citron ML, Johnston-Early A, Boyer M, et al. Patient-controlled analgesia for severe cancer pain. Arch Intern Med 1986; 146: 734-6.